MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced that its Canadian subsidiary, Sepracor Pharmaceuticals, Inc. (SPI; formerly Oryx Pharmaceuticals, Inc.), has submitted an application to the Therapeutic Products Directorate (TPD) of Health Canada for eslicarbazepine acetate as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. The proposed trade name for eslicarbazepine acetate in both the U.S. and Canada is STEDESA™.
